ANI Pharmaceuticals Announces Change of Independent Auditor

Key Points

• ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) has dismissed EisnerAmper LLP as its independent registered public accounting firm, effective April 1, 2026.
• Ernst & Young LLP (“EY”) has been appointed as the new independent registered public accounting firm, effective the same date.
• The decision was approved by the Audit and Finance Committee of ANI Pharmaceuticals’ Board of Directors.
• EisnerAmper’s most recent audit reports (for fiscal years ending December 31, 2024 and 2025) contained no adverse opinions, disclaimers, or qualifications regarding uncertainty, audit scope, or accounting principles.
• There were no disagreements or reportable events between ANI Pharmaceuticals and EisnerAmper during the relevant fiscal periods.
• EisnerAmper has provided a letter to the SEC confirming agreement with ANI Pharmaceuticals’ disclosures regarding the auditor change.
• ANI Pharmaceuticals did not consult with EY on any accounting matters prior to the appointment.

Details for Investors

On April 1, 2026, ANI Pharmaceuticals, Inc. (“ANI” or the “Company”), a publicly traded pharmaceutical company headquartered in Princeton, NJ, announced a significant change in its financial oversight. The Company notified EisnerAmper LLP (“EisnerAmper”) that it would be dismissed as ANI’s independent registered public accounting firm. The Audit and Finance Committee of the Board of Directors approved this decision, which took immediate effect.

In conjunction with this move, ANI Pharmaceuticals appointed Ernst & Young LLP (“EY”) as the Company’s new independent registered public accounting firm, effective April 1, 2026. EY will be responsible for auditing ANI’s financial statements for the fiscal year ending December 31, 2026 and onwards.

Implications for Shareholders and Potential Price Sensitivity

For investors, a change in external auditor is always a matter to scrutinize, as it can sometimes signal underlying issues or a shift in company direction. However, ANI Pharmaceuticals has disclosed that:

• The audit reports issued by EisnerAmper for the years ending December 31, 2024 and 2025 were clean — meaning no adverse opinions, no disclaimers, and no qualifications regarding uncertainty, audit scope, or accounting principles.
• During the audited periods and up to the date of dismissal, there were no disagreements between management and EisnerAmper on any matter of accounting principles or practices, financial statement disclosure, or audit procedures that would have required disclosure.
• There were no “reportable events” as defined under SEC regulations.
• EisnerAmper has reviewed ANI’s disclosures and has provided a letter to the SEC stating their agreement with the statements made by the Company regarding the auditor transition.
• ANI Pharmaceuticals did not consult with EY on any accounting matters, including any disagreements or reportable events, prior to EY’s formal appointment.

While the Company indicates no adverse circumstances surrounding the auditor change, such a transition is an event that investors should watch closely. The appointment of a “Big Four” firm like EY may enhance investor confidence in ANI’s financial reporting and corporate governance. However, any future restatements, changes in accounting practices, or differing audit opinions from the new auditor could have an impact on share value.

Background Information

• ANI Pharmaceuticals, Inc. trades on the Nasdaq Stock Market under the symbol “ANIP”.
• The Company’s principal executive offices are located at 104 Carnegie Center Drive, Suite 300, Princeton, NJ 08540.
• ANI’s fiscal year ends on December 31.

Next Steps and Shareholder Considerations

• The transition to EY as the new auditor will be closely observed during the next annual audit cycle.
• Shareholders should monitor subsequent filings for any updates or changes in financial reporting, accounting policies, or disclosures as a result of the auditor transition.
• No immediate negative signals have been reported as part of this change, and the Company’s controls and practices have not been flagged for deficiencies.

View ANI PHARMACEUTICALS INC Historical chart here